We would agree with Professor Taylor that the role of methacrylic acid co-polymer (used as an enteric coating, Eudragit, in certain brands of pancreatic enzymes) in developing fibrosing colonopathy (FC) is unclear and controversial [1]. The initial clinical report and subsequent epidemiological study linking FC to certain brands of high strength enzymes formed the basis of the subsequent advice of the Committee on Safety of Medicines (CSM)/Medicine control Agency (MCA) [2–4]. It was advised that the high strength enzymes Pancrease HL, Nutrizym 22 and Panzytrat 25,000 should not be used in children aged 15 years or less with cystic fibrosis (CF) and doses of more than 10,000 IU lipase per kg body weight per day of any preparation should be avoided. Since this advice, only three CF children in the UK have developed FC [5]. All were receiving Nutrizym GR, a low strength preparation but coated with Eudragit. In contrast, in the US, advice was to avoid high strength preparations containing more than 20,000 IU lipase per capsule and a total lipase intake ofmore than 10,000 IU/kg/day; there was no advice on brands [6]. However, despite this advice cases of FC continued to be reported to the US CF Foundation [7]. There appear to be other factors that are relevant to the development of cases of FA. From the evidence available, Eudragit may have contributed and avoidance has resulted in the disappearance of FC in children in the UK. It has been suggested that a high intake of lipase in itself is not a risk factor in the absence of methacrylic acid copolymer [8,9]. This seems to be supported by the absence of further UK cases despite the continuing high intake of predominantly Creon preparations in the UK, both standard and high strength [10], and Creon 25,000 in one paediatric CF centre [11].